Genfit: New EASL-EASD-EASO guidelines include NIS2+

Genfit announced the inclusion of NIS2 as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease, MASLD . The guidelines were developed as a joint effort by the European Association for the Study of the Liver or EASL , the European Association for the Study of Diabetes EASD, and the European Association for the Study of Obesity or EASO and provide healthcare providers an update on prevention, screening, diagnosis, follow-up and treatment for MASLD. The new guidelines were presented during the EASL congress 2024, and were released in the Journal of Hepatology. “The inclusion of NIS2+ in the EASL-EASD-EASO clinical guidelines is a major scientific recognition based on solid evidence that NIS2+ could play an important role in identifying patients that may benefit from emerging treatments for MASH,” commented Dean Hum, Chief Scientific Officer at GENFIT. “Additionally, GENFIT’s diagnostic technology featured as a monitoring treatment response in a Phase 2 study on tirzepatide’s safety and efficacy for MASH, and was recently presented during the Late Breaking session at EASL and jointly published in the New England Journal of Medicine3,” he added.